DBM-819
DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H+/K+-ATPase), with an IC50 value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC50 values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 331686-58-9
- 分子式: C23H27N3O2
- 分子量:377.48
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
化学情報
-
CAS 番号 331686-58-9
-
分子量 377.48
-
分子式 C23H27N3O2
-
SMILES
OCCCNC1=C(CCN2C3=CC=C(C=C3C)OC)C2=C(C=CC=C4C)C4=N1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Choi SJ, et al. In vitro metabolism of a new H(+)/K(+) ATPase inhibitor DBM-819 in liver microsomes using HPLC and electrospray mass spectrometry. Biomed Chromatogr. 2001 Dec;15(8):503-6. [Content Brief]
[2]. Kim EJ, et al. Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect. Biopharm Drug Dispos. 2001 Apr;22(3):119-28. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)